Sylvie — Courtois

Courtois has been a key contributor to several landmark studies evaluating the real-world effectiveness of disease-modifying therapies (DMTs). Her work often focuses on the transition between treatments and the long-term impact of specific medications on disease progression.

: One of her most notable recent contributions is the study of evolving treatment strategies for relapsing-remitting multiple sclerosis (RR-MS) . This research highlights a shift toward earlier initiation of high-efficacy treatments (like anti-CD20 monoclonal antibodies) to prevent disability accumulation from the disease onset. sylvie courtois

: She has also extensively researched the long-term benefits of natalizumab , particularly its ability to maintain "no evidence of disease activity" (NEDA-3) and its impact on the TYSTEN cohort over extended periods. Pediatric Multiple Sclerosis Long-term effect of natalizumab in patients with RRMS Courtois has been a key contributor to several